| Stereochemistry | ABSOLUTE |
| Molecular Formula | C13H14N2 |
| Molecular Weight | 198.2637 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
N[C@@H](CC1=CC=CC=N1)C2=CC=CC=C2
InChI
InChIKey=FWUQWDCOOWEXRY-ZDUSSCGKSA-N
InChI=1S/C13H14N2/c14-13(11-6-2-1-3-7-11)10-12-8-4-5-9-15-12/h1-9,13H,10,14H2/t13-/m0/s1
| Molecular Formula | C13H14N2 |
| Molecular Weight | 198.2637 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
CNS Activity
Originator
Approval Year
Sourcing
PubMed
Patents
Sample Use Guides
50-150 mg of the drug is given as a single intravenous (iv) infusion over 60 minutes.
Route of Administration:
Intravenous
Rat cortical neurons were exposed to NMDA (50 uM) or glutamate (50 uM) for 15 min, the treatment resulted in the death of 85-95% of the neurons during the next 24 h. Lanicemine inhibited the neurotoxicity at 50 uM, prevented the loss of membrane-associated protein kinase C activity and reduced by approximately 35% the magnitude of NMDA-triggered increases in intracellular free Ca2+ concentration in the cortical cultures.
|
|
SALT/SOLVATE -> PARENT | |||
|
|
TARGET -> INHIBITOR |
|
Showing 1 to 2 of 2 entries
